TheranosticTrials.org

Clinical Trial · NCT04941872

Comparison of 68Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT in Patients With Various Types of Cancer

Overview

To evaluate the potential usefulness of 68Ga-DOTA-2P(FAPI)2 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with 68Ga-DOTA-FAPI-46 PET/CT.

Sponsor

The First Affiliated Hospital of Xiamen University

Phase

N/A

Contacts

Long Sun, PhD (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT04941872

Drug / Compound

2P(FAPI)2

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA
Linker: 2P

FAPI-46

Isotope(s):
Target(s):
  • FAP
Ligand Class: Small Molecules
Chelator: DOTA

Eligibility

Inclusion

  • (iii) patients who had scheduled both 8Ga-DOTA-FAPI-46 and 68Ga-DOTA-2P(FAPI)2 PET/CT PET/CT scans;
  • (ii) patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);

Exclusion

  • (ii) patients with pregnancy;
  • (i) patients with non-malignant lesions;